E-Care Acceptability for Older People Undergoing Chemotherapy

NCT05408195 | Withdrawn

• 1 other identifier: RC31/19/0517
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The main objective of this pilot study is to evaluate the acceptability of clinical data collection using a semi-automated e-solution based on the use of text messaging among older adults undergoing chemotherapy treatment at home.

Conditions

Cancer

Keywords

older adults; nurses; smartphones; chemotherapy; geriatric oncology.

Outcome Measures

Primary Outcomes (1)

• Acceptance of semi-automated follow-up

  Proportion of patients who uploaded the application, Proportion of patients who received at least one questionnaire, Proportion of patients who answered at least one questionnaire, Completion questionnaire rate and answered questionnaire rate

  6 months of CHATBOT use

Study Arms (1)

CHATBOT users

EXPERIMENTAL

patients downloading and using the CHATBOT

Device: CHATBOT use

Interventions

CHATBOT use DEVICE

Patients benefiting from chemotherapy with outpatient follow-up (conventional follow-up by telephone calls) have the possibility to receive a weekly remote questionnaire (by email or SMS) via a CHATBOT on any terminal. This automated questionnaire collects data (completed by the patient and/or their caregivers) on tolerance and compliance to the care plan.

CHATBOT users

Eligibility Criteria

• Age: 70 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• Subjects of 70 years of age or older;
• Subjects undergoing chemotherapy treatment after a cancer diagnosis;
• Subjects managed by the oncogeriatrics team at the Toulouse University Hospital as part of an outpatient follow-up and followed by conventional telephone calls and CHATBOT support.

You may not qualify if:

• Patient's refusal to participate.
• Patient does not have sufficient equipment for downloading and using the CHATBOT tool
• Participant under guardianship, curatorship or safeguard of justice.

Sponsors & Collaborators

• University Hospital, Toulouse: lead

Study Sites (1)

CHU de Toulouse

Toulouse, France

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

• Antoine PIAU, MD PhD

  University Hospital, Toulouse

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 24, 2022
• First Posted: June 7, 2022
• Study Start: January 1, 2024
• Primary Completion: January 1, 2025
• Study Completion: January 1, 2025
• Last Updated: June 28, 2024

Record last verified: 2024-06

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)